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Murine modelThere is intense interest in understanding how the purine nucleoside adenosine functions in health and during
disease. In this review, we outline some of the evidence that implicates adenosine signaling as an important
metabolic signature to promote inﬂammatory resolution. Studies derived from cultured cell systems, animal
models and human patients have revealed that nucleotide metabolism is signiﬁcant component of the overall
inﬂammatory microenvironment. These studies have revealed a prominent role for the transcription factors
NF-κB and hypoxia-inducible factor (HIF) and that these molecules are post-translationally regulated through
similar components, namely the neddylation of cullinswithin the E3 ligase that are controlled through adenosine
receptor signaling. Studies deﬁning differences and similarities between these responses have taught us a
number of important lessons about the complexity of the inﬂammatory response. A clearer deﬁnition of these
pathways has provided new insight into disease pathogenesis and importantly, the potential for new therapeutic
targets.
© 2014 Curtis et al. Published byElsevier B.V. on behalf of the ResearchNetwork of Computational and Structural
Biotechnology. This is an open access article under the CC BY license
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Adenosine is a purine nucleoside that has long been implicated in
normal cell growth and metabolism and more recently has been
demonstrated topossess potent anti-inﬂammatoryproperties. Surprisinglyol of Medicine, 12700 East 19th
303 724 7235, fax: +1 303 724
tis).
on behalf of the Research Network oflittle is known about the actual mechanisms of adenosine-mediated
anti-inﬂammation. While signal transduction through the various
adenosine receptors is reasonably well characterized, less is known about
post-receptor signaling events and consequences of such signaling. One
recently appreciated mechanism suggests that adenosine acts on the
proteasomal degradation machinery that controls inﬂammation-
associated transcription factors. This short review focuses on speciﬁc
molecular pathways that have been identiﬁed downstream of
adenosine signaling, including NF-κB and hypoxia inducible factor
(HIF) pathways, and explores their role in inﬂammation, resolution
and as potential new targets for therapy.Computational and Structural Biotechnology. This is an open access article under the CC BY
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At sites of injury and inﬂammation, adenosine is released and plays
an important role in regulating inﬂammatory responses and limiting
inﬂammatory tissue destruction [1]. Increased levels of adenosine have
been detected during both inﬂammation and hypoxia and in these
conditions, adenosine is both anti-inﬂammatory and cytoprotective [2,
3]. The adenosine pathway has multiple points of regulation including
metabolism of purine nucleotides via CD39 (ectonucleoside triphosphate
diphosphohydrolase 1, E-NTPDase1) and CD73 (ecto-5′-nucleotidase,
Ecto5′NTase), signaling via adenosine A2A and A2B receptors, and
transport via ENT1/2 (equilibrative nucleoside transporters 1/2) [4,5].
Therefore, multiple potential therapeutic targets of the adenosine
pathway have been evaluated for various inﬂammatory diseases and
ischemia reperfusion disorders [6,7].
Recent work has deﬁned the relationship between adenosine,
adenosine receptor (AR) signaling, and anti-inﬂammation [4]. The
signal transduction through the various ARs has been well characterized,
however, less is known about the post-receptor events. Work in various
cell types has shown that adenosine inhibits NF-κB activation through a
number of distinctmechanisms, including elevation of intracellular cyclic
adenosine monophosphate (cAMP) and activation of protein kinase A
(PKA)which blocks IκB phosphorylation thus inhibiting NF-κB activation
[8], inhibition of tumor necrosis factor (TNF)-α-induced NF-κB activity
and subsequent gene expression by inhibition of nuclear translocation
of active NF-κB without inﬂuencing IκB phosphorylation or degradation
[9,10], and increased SUMO-1 modiﬁcations of IκBα by adenosine
inhibition of phosphorylation and degradation of IκBα, which attenuates
NF-κB activation [11]. Our work in recent years has found that adenosine
inhibits NF-κB through actions on proteasomal degradation of IκB
proteins via an alternative adenosine-mediated mechanism. Studies
using an NF-κB luciferase reporter assay conﬁrmed that adenosine,
generated under the adaptive pathway of hypoxic preconditioning,
signiﬁcantly suppressed NF-κB activation [12]. As previous studies had
demonstrated a connection between IκB degradation, NF-κB inhibition
and Cullin-1 (Cul-1) protein deneddylation [13,14], the neddylation
status of Cul-1 after AR stimulation revealed that adenosine indeed
modulated Cul-1 neddylation and further inﬂuenced IκB proteinFig. 1.Neddylation pathways inﬂuencing NF-κB andHIF-1α. Left, NF-κB pathway: Pro-inﬂamm
p-IκB by the Cul-1–Nedd8–βTRCP complex, culminating in its polyubiquitination and proteasom
achieved through a multi-enzyme process wherein DEN-1 cleaves the Nedd8 precursor to its m
inhibition of Nedd8 conjugation byMLN4924 through inhibition of the Nedd8-activating enzym
quenching pro-inﬂammatory signaling. The binding of adenosine to adenosine receptors (AdoR)
of DEN-1 activity by adenosine and AdoR. Right, HIF-1α pathway: In contrast to NF-κB, HIF-1α
Nedd8–pVHL complex. Pharmacological inhibition of Cul-2 neddylation using MLN4924 stabi
genes. Loss of DEN-1 also positively inﬂuences barrier function of intestinal epithelial cells.stabilization and downstream targets. Regulated protein degradation is
an essential part of cell signaling for many adaptive processes. The
proteasomal degradation of IκB (Fig. 1), which inhibits NF-κB, is but
one example of a rapid response by the cell to signal for growth, differen-
tiation, apoptosis, or inﬂammation. The E3 SCF ubiquitin ligase is speciﬁc
to the IκB family and is comprised of SKP1, Cul-1 and the F-box domain of
β-TrCP and is responsible for the polyubiquitination of IκB [15]. The COP9
signalsome (CSN) must conjugate the small protein Nedd8 to Cul-1 in
order for the E3 SCF to be active, and deneddylated Cul-1 therefore
inhibits the ubiquitination of IκB, inactivating NF-κB [16]. It is currently
unclear which of these adenosine-mediated pathways predominately
regulates NF-κB activity.
Onemechanism of deneddylation occurs through the deneddylase-1
(DEN-1, also called SENP8) protein. DEN-1 is a Nedd8-speciﬁc protease
that has isopeptidase activity capable of directly deneddylating cullin
targets [17,18]. The inﬂuence of these other cullin targets on pathways
that can mediate inﬂammation, such as Cullin-2 (Cul-2) and the HIF
pathway, and the potential inﬂuence of adenosine on DEN-1 activity
are areas currently being studied.
3. Adenosine and Ischemia and Reperfusion Injury
Ischemia-reperfusion injury is a pathologic condition characterized
by an initial restriction of blood supply, followed by the subsequent
restoration of perfusion and concomitant re-oxygenation. In its classic
manifestation, occlusion of a coronary artery is caused by a coronary
thrombus and results in a severe imbalance of metabolic supply and
demand causing tissue hypoxia [19]. In the second stage of the disease,
blood ﬂow is rapidly restored. Somewhat surprisingly, the restoration of
blood ﬂow along with re-oxygenation is in many instances associated
with an exacerbation of tissue injury and a profound inﬂammatory
response (so called “reperfusion injury”) [20].
A recent study provided new insights into potential mechanisms of
how adenosine and HIF-1 could function in mediating cardioprotection
from ischemia and reperfusion injury [21,22]. It has been known for
some time that one of the critical functions of HIF is the induction of
glycolytic enzymes, which are considered critical components of
enhancing the capacity of hypoxic or ischemic tissues to increaseatory stimuli, such as LPS, facilitate the phosphorylation of IκB, leading to the recognition of
al degradation. The conjugation of Nedd8 to Cul-1 is required for polyubiquitination and is
ature form, allowing for conjugation to cullin proteins. Loss of DEN-1, or pharmacological
e (NAE), prevents the activation of Cul-1, preventing the liberation of NF-κB from IκB and
also results in deneddylation of Cul-1. Studies are ongoing regarding a potential regulation
in its hydroxylated form is degraded by the proteasome after ubiquitination via the Cul-2–
lizes cellular HIF-1α levels, leading to increased transcription of pro-resolving HIF target
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or anoxic conditions [23,24] Interestingly, this function of HIF1A
involves the interaction with the circadian rhythm protein Period 2
(Per2), amoleculewhich is induced by adenosine 2B receptor activation
[22]. Indeed, HIF-dependent induction of the glycolytic program during
myocardial ischemia is completely abolished in Per2−/− mice [22].
Additional studies in Hif or Per2 reporter mice provided further
evidence for an interaction between HIF and PER in the heart. These
studies indicated that similar to the circadian alteration of Per2 levels
over a 24 h our time period, Hif1a exhibits a circadian expression
pattern [22,25]. Moreover, genetic ablation of Per2 in Hif reporter mice
arrested the circadian expression pattern of HIF, indicating a functional
interaction between HIF1A and PER2. Interestingly, light-induced
stabilization of cardiac Per2 expression also promoted increases in the
expression of glycolytic enzymes, and concomitant cardio-protection,
indicating that PER2/HIF1A interact during myocardial ischemia to
increase the anaerobic glycolytic capacity of the ischemic heart [22].
4. NF-κB and the Neddylation Pathway
Understanding the mechanisms that control responses to inﬂamma-
tion is important in developing effective therapies. One such condition
for which novel therapies are needed is sepsis. Recent work has demon-
strated that CD73-derived adenosinemay be beneﬁcial in sepsis [26], and
AR activation may offer a new therapeutic approach to manage sepsis
[27]. The mechanism of sepsis remains incompletely understood, though
loss of endothelial cell function and subsequent activation of the immune
system are hallmarks [28,29]. The NF-κB pathway is important for intra-
cellular pro-inﬂammatory signaling [30] and is regulated by Cullin-RING
ligases, as described above (Fig. 1).
In recent work, Ehrentraut et al. sought to identify the proximal
regulator that is central to the anti-inﬂammatory properties elicited by
adenosine in previous models of inﬂammation [31]. The discovery of
DEN-1 provided new insights into how Cul neddylation was regulated.
Therefore, in this study, the role of DEN-1-mediated neddylation during
inﬂammation was investigated using several approaches, including
knockdown and overexpression of DEN-1 in human endothelial cells.
Over 50% knockdown of DEN-1messagewas achieved in humanmicro-
vascular endothelial cells (HMEC-1), leading to an 85% loss of DEN-1
protein expression. Cul-1 neddylation was decreased in the DEN-1
knockdown cells and a decreased translocation of NF-κB subunit
p65 to the nucleus was observed after stimulation with LPS in the
knockdown cells. Overexpression of DEN-1 in HMEC-1 cells signiﬁcantly
inﬂuenced NF-κB responses as basal NF-κB reporter plasmid activity
increased by 2.8 ± 0.5 fold. These loss- and gain-of-function studies
clearly implicate DEN-1 as a critical component of vascular endothelial
NF-κB responses.
Recently, pharmacological inhibition of cullin neddylation has been
studied using a small molecular inhibitor, MLN4924. MLN4924, a
structural analog of adenosine monophosphate (AMP), functions by
inhibiting the Nedd8-activating enzyme (NAE), thereby inhibiting the
neddylation of cullin proteins including Cul-1 and Cul-2 [32] (Fig. 1).
WhenMLN4924was employed in theNF-κBpathway studies, Ehrentraut
et al. found that NF-κB luciferase reporter activity was decreased in
HMEC-1 cells, even after stimulation with LPS. Indeed, the inﬂuence of
MLN4924 on Cul-1 neddylation was conﬁrmed by western blot as
treatment of HMEC-1 cells with MLN4924 in the presence of LPS led to
Cul-1 deneddylation. The function of endothelial cellswas also inﬂuenced
as treatment with MLN4924 decreased the expression of ICAM-1
transcript and abrogated barrier dysfunction elicited by LPS as measured
by FITC-dextran ﬂux.
In translating these in vitro ﬁndings, the inﬂuence of disruption of
the neddylation pathway with regard to inﬂammation was studied
in vivo. Genetic studies are limited given the presumed embryonic
lethality of DEN-1 knockout, therefore MLN4924 was employed for
these purposes. MLN4924 is well tolerated in murine tumor models[32]. Mice were pre-exposed to MLN4924 for 1 h, followed by intraper-
itoneal LPS for 6 h before serum was collected to analyze cytokine and
chemokine levels [31]. Interestingly, pro-inﬂammatory cytokines, such
as IL-1β, IFNγ and TNF-α were downregulated in LPS-treated mice
that had received MLN4924 pre-treatment. These in vivo observations
reveal a potent anti-inﬂammatory role for MLN4924 and parallel
deneddylation of Cul-1. Taken together, these results demonstrate that
inﬂammation actively deneddylates Cul-1, DEN-1 is central to the
control of NF-κB activation, and the neddylation inhibitor MLN4924
inhibits NF-κB activity. The role of ARs inmurine dextran sulfate sodium
(DSS)-colitis as a model of inﬂammation was also previously explored
and revealed the importance of the A2BA receptor (A2BAR) [33]. The
severity of colitis was increased in Aa2br(−/−) mice relative to
Aa2br(+/+) controls, as reﬂected by increased weight loss, colonic
shortening, and disease activity indices. Additionally, Cul-1 was consti-
tutively neddylated in the Aa2br(−/−) mice compared to the controls,
again providing a link between adenosine signaling, Cul-1 neddylation
and the resolution of inﬂammation.
5. HIF-1α and the Neddylation Pathway
Previous work has indicated that the microenvironment of an
inﬂammatory lesion is depleted of oxygen and can be characterized by
the generation of large amounts of adenine nucleotide metabolites
[34,35]. HIF proteins function as one of the master regulators of oxygen
homeostasis. HIF coordinates adenine nucleotide metabolism and
regulates adenosine signaling [4]. Together, hypoxia and adenosine
have protective actions during inﬂammation, promoting resolution
and tissue repair. As mentioned previously, an analogous E3 ligase
complex exists upstream of the alpha subunits of HIF, which is
comprised of Cul-2, Elongin B/C and the von Hippel–Lindau protein
(pVHL). Similar to the Cul-1–IκB–NF-κB axis, neddylation of Cul-2 is
required for the ubiquitination of hydroxylated HIF-1α in normoxic
conditions (Fig. 1). The alpha subunits of HIF are hydroxylated by prolyl
hydroxylases (PHDs) to target the HIF subunits for degradation. In the
absence of oxygen, the alpha subunits of HIF are not targeted for
degradation and therefore translocate into the nucleus to dimerize
with constitutively expressed HIF-1β subunits, turning on targeting
genes [4]. PHD inhibitors have been previously investigated for their
therapeutic potential in various disease models, such as murine colitis
[36,37].
In our recentwork, an alternativemechanismof HIF-1α stabilization
via the Cul-2 neddylation pathway was explored in intestinal epithelial
cells [38]. Given the previous results regarding inhibition of the NF-κB
pathway after Cul-1 deneddylation both genetically through DEN-1
knockdown and pharmacologically through MLN4924 treatment, we
hypothesized that stabilization of HIF-1α by Cul-2 deneddylation
would be protective in mucosal inﬂammation. Indeed, studies in HeLa
cells as models of epithelial cells revealed robust HIF-1α stabilization
and Cul-2 deneddylation after acute treatments with low concentra-
tions ofMLN4924. The functional consequences of this HIF-1α stabiliza-
tion were investigated. HIF-1α activity signiﬁcantly increased after
treatment with MLN4924 as measured by an HRE (hypoxia response
element) luciferase reporter assay, and the HIF-1α target genes
BNIP3L and enolase-1 were signiﬁcantly upregulated 1 and 2 h after
treatment with MLN4924.
The knockdown of DEN-1 in T84 cells, an intestinal epithelial cell
line, via lentivirus shRNA revealed decreased Cul-2 neddylation at
baseline, increased barrier formation over time and an increased rate
of resolution after a calcium switch assay, compared to cells infected
with a non-targeting control lentivirus shRNA. The protective role of
HIF and the contribution of the neddylation pathway were further
conﬁrmed in a DSS-colitis murine model. Mice treated with DSS that
received a pre-treatment of MLN4924 displayed decreased percent
body weight loss, decreased colon shortening and decreased histologic
injury scores, compared to mice receiving DSS and vehicle treatment.
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MLN4924 under inﬂammatory conditions can be protective when HIF
stabilization is promoted. Interestingly, HIF hydroxylases can also
regulate NF-κB, and NF-κB is thought to be protective in the intestinal
epithelium via the inhibition of enterocyte apoptosis [36,39,40].
Therefore, the ability of MLN4924 to promote HIF signaling and inhibit
NF-κB signaling should be carefully balanced for the neddylation
pathway to represent a novel therapeutic target for inﬂammatory
bowel diseases. Studies to address these concepts are currently ongoing.
6. Conclusion
The interplay of molecular signaling that directs inﬂammation
represents a complex system. Understanding the crosstalk between
these signals and how they might be modulated to treat inﬂammation-
related diseases is an important area of research. Adenosine is amolecule
that exerts broad biological actions and new studies have shed light on its
inﬂuence in pivotal inﬂammatory pathways, including NF-κB and HIF.
Using the mechanisms of post-receptor adenosine signaling that have
been recently discovered, new potential therapeutic targets have been
identiﬁed for conditions such as sepsis and IBD that warrant additional
study.
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